Biomedica Immunoassays

525 €

Contact us!

FGF23 (C-terminal) ELISA

Human multi-matrix ELISA for serum and plasma samples. - Standardized quantification in pmol/l. - CE marked - for IVD use in EU.


Assay characteristics:

Cat.No.: BI-20702
Method: Sandwich ELISA, HRP/TMB, 12x8-well strips
Sample type:Serum, plasma (EDTA, heparin, citrate)
Standard range:0-20 pmol/l (7 serum based standards)
Standard points:0/0.2/0.6/1.8/5/10/20 pmol/l
Control:2 serum based controls
Sample size:50 µl / well
Incubation time:20-24 h / 1 h / 30 min
Unit conversion:1 pg/ml = 0.133 pmol/l (MW: 7.52 kDa)

LOD: 0.08 pmol/l (0 pmol/l + 3 SD); LLOQ: 0.1 pmol/l

Intra-assay: 2 samples of known concentrations were tested 6 times within 1 kit lot by 1 operator.
Inter-assay: 2 samples of known concentrations were tested 10 times within 2 different kit lots by 4 different operators.

Intra-assay (n=6) Sample 1 Sample 2
Mean (pmol/l) 0.6 10.0
SD (pmol/l) 0.07 0.06
CV (%) 12 6
Inter-assay (n=10) Sample 1 Sample 2
Mean (pmol/l) 0.6 9.9
SD (pmol/l) 0.06 0.50
CV (%) 10 5

The recovery of FGF23 was evaluated by adding 2 concentrations of human recombinant C-terminal FGF23 (5 + 10 pmol/l) to different human sample matrices. 

Matrix Mean S/R [% ]
+5 pmol/l +10 pmol/l
Serum (n=13) 96 89
EDTA plasma (n=7) 97 94
Heparin plasma (n=8) 101 92
Citrate plasma (n=7) 100 90

Dilution linearity:
Dilution linearity was assessed by serially diluting samples containing endogenous FGF23 with assay buffer.

Matrix Mean R of dilution steps [%]
1+1 1+3 1+7
Serum (n=9) 105 100 108
EDTA plasma (n=4) 103 103 106
Heparin plasma (n=10) 107 106 104
Citrate plasma (n=5) 102 106 101

The assay measures both intact FGF23 and C-terminal FGF23. The assay recognizes endogenous (natural) and recombinant human FGF23.

This immunoassay is calibrated against recombinant human FGF23 (C-terminal) peptide.

Values from apparently healthy individuals:
Median serum (n=35): 0.8 pmol/l
Median EDTA plasma (n=22): 1.3 pmol/l
Median heparin plasma (n=22): 1.2 pmol/l
Median citrate plasma (n=30): 1.4 pmol/l
It is recommended to establish the normal range for each laboratory.

Principle of the assay: 

Manual ELISAs - easily adaptable for automation! 

Back to top


Click link for:


Biomedica Analytical Service Quotation Form

Back to top


Click link for: 

BI-20702 FGF23 ELISA Validation Data (S/R, dilution linearity, precision, ...)

BI-20702 FGF23 ELISA Sample Stability Data

Back to top


FGF23 (fibroblast growth factor 23) is a 32-kDa protein with 251 amino acids that is proteolytically processed between arginine179 and serine180 to generate N-terminal and C-terminal fragments. FGF23 is mainly secreted by osteocytes and controls phosphate and 1,25(OH)2 vitamin D homeostasis.

Click here for MSDS 
Click here for PRODUCT LEAFLET 
Click here for CORRELATION DATA between different FGF23 assays

Click here for PRESS RELEASE

Klicken Sie hier für den FGF23 ELISA Flyer in deutscher Sprache. 

Back to top


Click here to download our FGF23 Reference List.

Oral iron supplementation with sodium ferrous citrate reduces the serum intact and cterminal fibroblast growth factor 23 levels of maintenance haemodialysis patients
Kazuomi Yamashita, Sonoo Mizuiri, Yoshiko Nishizawa, Shigemoto Kenichiro, Shigehiro Doi, and Takao Masaki
Nephrology (Carlton). 2017 Dec; 22(12): 947–953.
PMCID: PMC5725691

Fibroblast growth factor 23 in patients with acute dyspnea: Data from the Akershus Cardiac Examination (ACE) 2 Study.
Magnus Nakrem Lyngbakkena, Mohammad Osman Perveza, Jon Brynildsena, Marit Holmefjord Pedersena, Janne Sølvernesa, Geir Christensen, Arne Didrik Høisethb, Torbjørn Omland, Helge Røsjø.
Clin Biochem. 2017 Oct 24. pii: S0009-9120(17)30670-7.
PMID: 29074091

Sex and Iron Modify Fibroblast Growth Factor 23 (FGF23) Concentration in 1-Year-Old Children.
Elisa Holmlund-Suila Maria Enlund-Cerullo Saara Valkama Helena Hauta-alus Jenni Rosendahl Otto Helve Timo Hytinantti Heli Viljakainen Sture Andersson Outi Mäkitie.
J Clin Endocrinol Metab. 2017 Dec 1;102(12):4526-4533.
PMID: 29029193

Fibroblast Growth-factor 23 and Calcium-binding Proteins are not Associated with Chronic Itch in Patients on Haemodialysis
Thomas Mettang, Kevin Kunzmann, Heinz-Jürgen Roth and Elke Weisshaar
Acta Derm Venereol 2017; 97: 381–382
PMID: 27671605

The response of fibroblast growth factor-23 to teriparatide in postmenopausal osteoporosis.
Fatma Gossiel, Eugene McCloskey, Jennifer Walsh, Kim Naylor, Nicola Peel & Richard Eastell.
Bone Abstracts (2016) 5 OC3.4.

FGF23 and vitamin D metabolism in chronic kidney disease – mineral bone disorder.
Isabelle Piec, Allison Chipchase, Holly Nicholls, Christopher Washbourne, Jonathan Tang & William D. Fraser.
Bone Abstracts
(2016) 5 P469.

Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome-induced hypophosphatemia
Shunsuke Goto, Hideki Fujii, Keiji Kono, Kentaro Watanabe, Kentaro Nakai and Shinichi Nishi
Clinical Kidney Journal, 2016, 9(5): 677–681
PMCID: PMC5036911

Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerone in primary hyperparathyroidism trial. Verheyen N, Fahrleitner-Pammer A, Pieske B, Meinitzer A, Belyavskiy E, Wetzel J, Gaksch M, Grübler MR, Catena C, Sechi LA, Van Ballegooijen AJ, Brandenburg VM, Scharnagl H, Perl S, Brussee H, März W, Pilz S, Tomaschitz A.
J Hypertens. 2016 Sep;34(9):1778-86
PMID: 27379537

Serum FGF23 levels may not be associated with serum phosphate and 1,25-dihydroxyvitamin D levels in patients with Fanconi syndrome–induced hypophosphatemia
Shunsuke Goto, Hideki Fujii, Keiji Kono, Kentaro Watanabe, Kentaro Nakai, and Shinichi Nishi
Clinical Kidney Journal,
Oct 2016; 9: 677-681.
PMCID: PMC5036911

Isabelle Piec, Allison Chipchase, Holly Nicholls, Christopher Washbourne, Jonathan Tang, and William D. Fraser
Nephrol. Dial. Transplant.,
May 2016; 31: i460.

Back to top